These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 26359511)

  • 1. Purinergic Receptors in Thrombosis and Inflammation.
    Hechler B; Gachet C
    Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2307-15. PubMed ID: 26359511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The platelet P2 receptors in arterial thrombosis.
    Gachet C; Léon C; Hechler B
    Blood Cells Mol Dis; 2006; 36(2):223-7. PubMed ID: 16466948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agonists and antagonists for P2 receptors.
    Jacobson KA; Costanzi S; Joshi BV; Besada P; Shin DH; Ko H; Ivanov AA; Mamedova L
    Novartis Found Symp; 2006; 276():58-68; discussion 68-72, 107-12, 275-81. PubMed ID: 16805423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P2 receptors, platelet function and pharmacological implications.
    Gachet C
    Thromb Haemost; 2008 Mar; 99(3):466-72. PubMed ID: 18327393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential Therapeutic Applications of P2 Receptor Antagonists: From Bench to Clinical Trials.
    da Silva Ferreira NC; Alves LA; Soares-Bezerra RJ
    Curr Drug Targets; 2019; 20(9):919-937. PubMed ID: 30760187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P2 receptors and platelet activation.
    Kunapuli SP
    ScientificWorldJournal; 2002 Feb; 2():424-33. PubMed ID: 12806027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purinergic receptors mediate endothelial dysfunction and participate in atherosclerosis.
    Wu XM; Zhang N; Li JS; Yang ZH; Huang XL; Yang XF
    Purinergic Signal; 2023 Mar; 19(1):265-272. PubMed ID: 34981330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P2 Receptors in Cardiac Myocyte Pathophysiology and Mechanotransduction.
    Woo SH; Trinh TN
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute arterial thrombosis in the absence of inflammation: the stress-related anti-inflammatory hormone ACTH participates in platelet-mediated thrombosis.
    Pozzi AO; Bernardo E; Coronado MT; Punchard MA; González P; Fantidis P
    Atherosclerosis; 2009 May; 204(1):79-84. PubMed ID: 18834983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of P2 receptor subtypes producing dilation in rat intracerebral arterioles.
    Horiuchi T; Dietrich HH; Hongo K; Dacey RG
    Stroke; 2003 Jun; 34(6):1473-8. PubMed ID: 12730558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purinergic signaling in kidney disease.
    Menzies RI; Tam FW; Unwin RJ; Bailey MA
    Kidney Int; 2017 Feb; 91(2):315-323. PubMed ID: 27780585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P2Y12 receptor in platelet activation.
    Kim S; Kunapuli SP
    Platelets; 2011; 22(1):56-60. PubMed ID: 21231822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P2Y
    Mansour A; Bachelot-Loza C; Nesseler N; Gaussem P; Gouin-Thibault I
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32092903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Action of natural products on p2 receptors: a reinvented era for drug discovery.
    Faria R; Ferreira L; Bezerra R; Frutuoso V; Alves L
    Molecules; 2012 Nov; 17(11):13009-25. PubMed ID: 23117439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P2Y6 deficiency limits vascular inflammation and atherosclerosis in mice.
    Stachon P; Peikert A; Michel NA; Hergeth S; Marchini T; Wolf D; Dufner B; Hoppe N; Ayata CK; Grimm M; Cicko S; Schulte L; Reinöhl J; von zur Muhlen C; Bode C; Idzko M; Zirlik A
    Arterioscler Thromb Vasc Biol; 2014 Oct; 34(10):2237-45. PubMed ID: 25104800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The platelet ATP and ADP receptors.
    Oury C; Toth-Zsamboki E; Vermylen J; Hoylaerts MF
    Curr Pharm Des; 2006; 12(7):859-75. PubMed ID: 16515502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research articleHemolysis in human erythrocytes by Clostridium perfringens epsilon toxin requires activation of P2 receptors.
    Gao J; Xin W; Huang J; Ji B; Gao S; Chen L; Kang L; Yang H; Shen X; Zhao B; Wang J
    Virulence; 2018; 9(1):1601-1614. PubMed ID: 30277122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting P2 receptors in purinergic signaling: a new strategy of active ingredients in traditional Chinese herbals for diseases treatment.
    Ai X; Dong X; Guo Y; Yang P; Hou Y; Bai J; Zhang S; Wang X
    Purinergic Signal; 2021 Jun; 17(2):229-240. PubMed ID: 33751327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of purinergic receptor polymorphisms in human bone.
    Wesselius A; Bours MJ; Agrawal A; Gartland A; Dagnelie PC; Schwarz P; Jorgensen NR
    Front Biosci (Landmark Ed); 2011 Jun; 16(7):2572-85. PubMed ID: 21622196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P2 receptor antagonist PPADS inhibits mesangial cell proliferation in experimental mesangial proliferative glomerulonephritis.
    Rost S; Daniel C; Schulze-Lohoff E; Bäumert HG; Lambrecht G; Hugo C
    Kidney Int; 2002 Nov; 62(5):1659-71. PubMed ID: 12371966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.